Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

Intellia also separately announced positive topline data today from the Phase 3 HAELO clinical trial of lonvo-z in HAE. The trial met its primary and all key secondary endpoints, demonstrating that a ...
Hosted on MSN

Intellia's one-time CRISPR therapy shows strong Phase 3 results

Intellia Therapeutics reported that its in vivo CRISPR therapy, lonvo-z, met all primary and secondary endpoints in a Phase 3 ...
MobiHealthNews

FDA clears application for CRISPR RNA-editing therapy developed using AI

Global clinical-stage biotech company HuidaGene Therapeutics has received FDA clearance to move forward with its application for its investigational drug, a CRISPR/Cas13 RNA-editing therapy to treat ...
Business Wire

Flashpoint Therapeutics Announces Major Publication Supporting Application of its Proprietary Structural Nanomedicine Platform to CRISPR-based Therapeutics

CRISPR gene editing machinery holds the potential to transform the treatment of numerous diseases, but it requires effective delivery systems to get into tissues and ...
Labroots

From Discovery to Clinic: Comprehensive CRISPR Solutions for Therapeutic Development / mRNA-LNP Strategies for Gene Editing Application

CRISPR gene editing has revolutionized the field of molecular biology, offering precise, efficient, and versatile tools for genome modification. The technology has rapidly evolved beyond the original ...
EurekAlert!

A systematic approach for CRISPR application in grapes for disease resistance by targeting susceptibility (S) gene(s). (IMAGE)

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...